Use in pregnancy: Use of losartan during the 2nd and 3rd trimester of pregnancy may cause low blood pressure or severe kidney failure and is harmful, if not fatal to the fetus or infant. A case of oligohydramnios (decreased amniotic fluid), fetal effects and subsequent fetal death were reported in a patient exposed to losartan during 20-31 weeks of pregnancy. Treatment with losartan should be discontinued with the 1st sign of pregnancy.
Use in lactation: The excretion of losartan in breast milk has not yet been established. In a study done in animals, losartan was found to pass into the milk of lactating rats. Thus, caution should be taken when administering Kardiostan to lactating mothers.